Compile Data Set for Download or QSAR
Report error Found 1911 with Last Name = 'strum' and Initial = 'jc'
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.160nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.160nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.160nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253965(US9464092, EEE | US9527857, EEE)
Affinity DataIC50: 0.200nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253965(US9464092, EEE | US9527857, EEE)
Affinity DataIC50: 0.200nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.300nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.300nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.300nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.340nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.340nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.340nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253910(US9464092, B | US9527857, B)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253910(US9464092, B | US9527857, B)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253910(US9464092, B | US9527857, B)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253935(US9464092, AA | US9527857, AA)
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253935(US9464092, AA | US9527857, AA)
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253926(US9464092, R | US9527857, R)
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253926(US9464092, R | US9527857, R)
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253926(US9464092, R | US9527857, R)
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253935(US9464092, AA | US9527857, AA)
Affinity DataIC50: 0.5nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
US Patent

TargetCDK2/Cyclin-E2(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 0.560nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 0.560nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601935(US11643416, Compound 3 | 4-((3'-oxo-2',3'-dihydro-...)
Affinity DataIC50: 0.560nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 0.627nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253925(US9464092, Q | US9527857, Q | US10189849, Compound...)
Affinity DataIC50: 0.627nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253929(US9464092, U | US9527857, U)
Affinity DataIC50: 0.655nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253929(US9464092, U | US9527857, U)
Affinity DataIC50: 0.655nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 5(Human)
Pharmacosmos Holding

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.680nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.680nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
US Patent

TargetCyclin-dependent kinase 5 activator 1(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.680nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253918(US9464092, J | US9527857, J)
Affinity DataIC50: 0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253929(US9464092, U | US9527857, U)
Affinity DataIC50: 0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/25/2018
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253918(US9464092, J | US9527857, J)
Affinity DataIC50: 0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253918(US9464092, J | US9527857, J)
Affinity DataIC50: 0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Gi Therapeutics

US Patent
LigandPNGBDBM253929(US9464092, U | US9527857, U)
Affinity DataIC50: 0.700nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2017
Entry Details
US Patent

Displayed 1 to 50 (of 1911 total ) | Next | Last >>
Jump to: